Exiqon to Develop microRNA-Detection Products for Luminex's xMAP Platform | GenomeWeb
NEW YORK (GenomeWeb News) – Luminex and Exiqon said today that they have signed an agreement to co-develop and commercialize microRNA products for Luminex’s xMAP platform.
Under the terms of the agreement, Exiqon will develop and manufacture microRNA detection chemistries on behalf of the Luminex Bioscience Group.
The final microRNA products will be based on Luminex's xMAP instruments and Exiqon's Locked Nucleic Acid probes, nucleotide analogs that bind to RNA and DNA targets.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: modern European bison analysis, phased diploid genome assembly algorithms, and more.

Actress Jennifer Lopez is working with NBC on a CRISPR-inspired television show, according to the Hollywood Reporter.

Researchers trace the origin of one human papillomavirus lineage to Neanderthals or Denisovans, Vox reports.

The BabySeq project faces lower-than-expected enrollment rates, according to ScienceInsider.